Overview

Myocardial Blood Flow by PET and N-13 Ammonia During Regadenoson vs Adenosine Stress

Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
Blockage of the heart arteries (coronary artery disease) can lead to angina (chest pain), heart attacks, heart failure, and/or death. Positron emission tomography (PET) stress myocardial perfusion imaging (MPI) is a powerful tool to help identify blockages in the coronary arteries. During the PET MPI test, a drug is given to mimic the effects of exercise on the heart. The study was done to measure blood flow to the heart using two similar drugs approved to mimic the effects of exercise on the heart in people during a heart stress test. The first drug, called adenosine, has been approved for this use for several decades. The second drug, called regadenoson, was approved in 2008. The investigators were looking at whether the increase in blood flow to the heart with the newer drug (regadenoson) was similar to the increase in blood flow with the older drug (adenosine). This information is important for the use of these drugs in patients and for interpreting the blood flow values.
Phase:
N/A
Details
Lead Sponsor:
Mayo Clinic
Collaborator:
Astellas Pharma Inc
Treatments:
Adenosine
Regadenoson